Several factors may underlie this discrepancy: First, predominant use of type 1 diabetes models (STZ-induced mice) in preclinical studies inadequately replicates the complex metabolic milieu of human type 2 DKD, particularly regarding insulin resistance and dyslipidemia interactions. This evidence concerns the gene INS and metabolic syndrome.